Introduction {#S1}
============

Nanoparticles (NPs) have unique sizes, shapes, and structures, and this makes them ideal components for various applications ([@B6]). Silver nanoparticles (AgNPs), in particular, are exponentially used in medical, health, industrial, and precision agricultural sectors because of their unique features, such as chemical, optical, electrical, and thermal properties ([@B68]; [@B9]). Moreover, AgNPs are usually added to the polymeric matrices of food packaging to enhance food protection to extend its shelf-life. However, AgNPs may transfer and accumulate through the food chain, risking the human health ([@B14]; [@B57]). The effects of AgNPs on the intestinal human microbiota, the so far neglected "essential organ" ([@B34]), should be considered. The microbiota provides several advantages to the host through a variety of physiological functions: host immunity promotion, pathogens control, and energy harvest ([@B56]). Alterations in the intestinal microbiota have been associated with many different diseases, ranging from metabolic syndrome to diabetes atherosclerosis, to colorectal cancer ([@B64]).

In the human gastrointestinal microbiota, *Escherichia coli* can commonly exist as a commensal, a probiotic, or a pathogenic bacterium ([@B39]). To enlighten the effect of ingested AgNPs on intestinal bacterial biofilm and human intestinal epithelial cells, we recently analyzed the physiological response of a model system composed of *E. coli* monospecies biofilm and Caco-2 cells exposed to 1 μg/ml of AgNPs ([@B17]). Previously, it was claimed that a AgNP concentration of 1 μg/ml is representative of actual food-related ingestion ([@B18]; [@B25]; [@B14]). In [@B17], it was demonstrated that (1) bacterial biofilm plays an important role in protecting intestinal epithelial cells from AgNPs genotoxic effects, and (2) under anaerobic conditions, AgNPs seriously impact the *E. coli* biofilm.

This study aimed to explore the proteomic changes that occur when *E. coli* biofilm is exposed to AgNPs. To this end, *E. coli* biofilm was cultured using Transwell setup as described in [@B17]. AgNP exposure was performed to simulate the chronic and/or the acute effects of AgNPs on mature bacterial biofilms.

To investigate the impact of silver nanoparticles at realistic concentrations, we evaluated the chronic and the acute effects of sublethal AgNP doses at 1 and 10 μg/ml. We used a new proteomic approach based on shotgun nanoflow liquid chromatography--tandem mass spectrometry (LC-MS/MS) to obtain a global view of *E. coli* biofilm responses to the different AgNP exposures. We have thus highlighted protein changes triggered by AgNPs and identified common responses among the treatments as well as specific alterations.

Materials and Methods {#S2}
=====================

Silver Nanoparticles {#S2.SS1}
--------------------

The AgNPs were purchased from BioPure, NanoComposix (San Diego, CA, United States). According to the supplier, their hydrodynamic diameter is \<20 nm, and their negative zeta potential is −27.3 mV (Malvern Zetasizer Nano ZS). AgNP size was assessed to be 14 ± 0.3 nm using transmission electron microscopy (TEM) by our team's previous work ([@B16]). AgNPs were stored at 4°C and, just before use, diluted to 1 or 10 μg/ml in bidistilled water or in Tryptic soy broth medium (Conda, Italy).

Experimental Setup and Bacterial Biofilm Exposure to AgNPs {#S2.SS2}
----------------------------------------------------------

*Escherichia coli* MG 1655 biofilms were grown under anaerobic conditions on polycarbonate membranes (PC, Whatman Nucleopore, 2.5 cm diamater, 0.2 μm pore diameter) in Transwell systems (Greiner bio-one) as described by [@B17]. Briefly, polycarbonate membranes inoculated with 5 × 10^6^ cells were placed in the Transwell inserts. One milliliter of prereduced Tryptic soy broth medium with and one without 1 μg/ml AgNPs were added to the plate wells (basolateral medium). As 1 μg/ml represented the realistic human intake dosage, both the acute and chronic treatments were evaluated at this concentration. Three different treatments were assayed: (1) AgNPs added for 24 h directly onto the surface of an established biofilm, which was pregrown for 72 h without AgNPs (acute treatment, effect on established biofilm); (2) biofilm grown for 96 h with the addition of 1 μg/ml AgNPs dispersed in the basolateral medium (chronic treatment, effect on biofilm formation); (3) biofilm grown for 72 h with the addition of 1 μg/ml AgNPs dispersed in the basolateral medium and then further treated for 24 h with 10 μg/ml AgNPs added directly onto the surface of the established biofilm (chronic + acute treatment, effect of a short and aggressive AgNPs exposure to an adapted biofilm).

The controls for all treatments were defined as pristine biofilms grown for 96 h. Experiments were conducted in triplicate. The growth profile and reactive oxygen species (ROS) generation of *E. coli* under condition 1 (acute treatment) and condition 2 (chronic treatment) compared to control samples can be found in [@B17].

Liquid Chromatography--Mass Spectrometry Analysis {#S2.SS3}
-------------------------------------------------

After treatments, polycarbonate membranes with adhering biofilm were removed from the Transwell setups, transferred to tubes containing 1 ml of sterile phosphate-buffered saline solution (Medicago AB, Uppsala, Sweden), vortexed for 1 min, and sonicated for 3 min in a water bath (Sonica Ultrasonic Cleaner, Soltec, Milan, Italy). The cell pellet was resuspended in 4% (*w*/*v*) sodium dodecyl sulfate, 100 mM Tris--HCl pH 7.6 and 100 mM dithiothreitol, boiled for 5 min and centrifuged for 30 min at 13,000 rpm ([@B35]). Proteins were quantified with 2-D Quant Kit (GE healthcare); 200 μg of protein was then trypsinized using the two-digestion-filter-aided sample preparation method ([@B63]). Digested samples (five replicates for each treatment) were directly analyzed on a QExactive mass spectrometer coupled to a nano EasyLC 1000 (Thermo Fisher Scientific Inc., Waltham, MA, United States). The solvent composition for channel A was 0.1% formic acid, while for channel B, it was 0.1% formic acid and 99.9% acetonitrile. For each sample, 4 μl of peptides was loaded on a self-made column (diameter × length: 75 μm × 150 mm) packed with reverse-phase C18 material (ReproSil-Pur 120 C18-AQ, 1.9 μm; Dr. Maisch GmbH, Ammerbuch, Germany) and eluted at a flowrate of 300 nl/min with a gradient from 2 to 35% B in 80 min, from 35 to 47% B in 4 min, and from 47 to 98% B also in 4 min. Samples were acquired randomly. The mass spectrometer was operated in data-dependent mode, acquiring full-scan MS spectra (300--1,700 *m*/*z*) at a resolution of 70,000 at 200 *m*/*z* after accumulation to a target value of 3,000,000, followed by higher-energy collision dissociation fragmentation on the 12 most intense signals per cycle. Higher-energy collision dissociation spectra were acquired at a resolution of 35,000 using a normalized collision energy of 25 and a maximum injection time of 120 ms. The automatic gain control was set to 50,000 ions. Charge state screening was enabled, and singly and unassigned charge states were rejected. Only precursors with an intensity above 8,300 were selected for MS/MS (2% underfill ratio). Precursor masses previously selected for MS/MS measurement were excluded from further selection for 30 s, and the exclusion window was set at 10 ppm. The samples were acquired using internal lock mass calibration on *m*/*z* 371.1010 and 445.1200.

LC-MS/MS Data Analysis {#S2.SS4}
----------------------

Raw data obtained from the mass spectrometer were processed with MaxQuant v. 1.5.3.3^[1](#footnote1){ref-type="fn"}^ for peptide identification and quantifications. Identification was performed with MaxQuant integrated Andromeda search engine against the UniProt *E. coli* protein database (1,352,175 entries), downloaded September 29, 2016. The search criteria were the following: two missed cleavages, fixed modification of cysteine (carbamidomethylation), variable modifications of methionine (oxidation) and phosphorylation on serine, threonine, and tyrosine, and minimum peptide length of six amino acids. The minimum criteria for protein identification were two peptides and one unique peptide and precursor mass tolerance of 4.5 ppm for the main search. Label-free quantification, the match between runs (time window of 0.7 min), and the target-decoy search strategy (revert mode) options were enabled. Identifications were accepted with a false discovery rate (FDR) of 1% for peptide and proteins. The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE ([@B38]) partner repository under the dataset identifier PXD014096.

Proteomics Data Processing {#S2.SS5}
--------------------------

Once identified, all protein groups without contaminants and decoy entries as well as groups without "only identified by site" were chosen. Resulting protein groups were considered as identified when values were detected in at least two biological replicates and in one analytical group. This process led to missing values for one or the other condition. Missing values were estimated from the dataset by an in-house tool, based on two criteria for each sample, depending on whether one or more missing values were observed for each entry. When two values were available, the imputation of the missing value was set to a random value within an interval of one-fourth of the entire sample standard deviation centered on the entry average. While only one or no value was available, the imputation of the missing value was set to a random value within an interval of one-fourth of the standard deviation of all sample values centered on the global minimum value of all samples in the dataset.

Statistical Analysis {#S2.SS6}
--------------------

To determine the differentially expressed proteins (DEPs) among considered conditions, we performed a multiple sample test using analysis of variance (ANOVA) with a permutation-based FDR cutoff of 0.05. Statistical analysis was performed on each dataset (means ± SD, *n* = 4) with custom *R* scripts. One-way ANOVA and *post hoc* Tukey's test were done using two R statistical packages, limma, and cp4p^[2](#footnote2){ref-type="fn"}^.

Principal Component Analysis and Hierarchical Clustering {#S2.SS7}
--------------------------------------------------------

To assess the quality of our datasets, Perseus software (MaxQuant, v1.11, Martinsried, Germany) was used for PCA. We also built a Venn diagram by submitting to VENNY^[3](#footnote3){ref-type="fn"}^ the entire dataset of identified and quantified proteins.

Hierarchical clustering analysis was performed using Perseus with the following settings: Row, Column distance calculated using the Euclidean algorithm; Row, Column linkage Complete.

Hierarchical clustering heat map of significantly changing proteins was performed using the *Z*-score calculation on log2 intensity values.

EcoCyc Analyses {#S2.SS8}
---------------

For all differentially abundant proteins, present in each selected cluster, a Blastp was performed against ecoli.fsa database (4,287 sequences, 1,342,714 total letters) to obtain EcoCyc accession IDs from Uniprot protein IDs.

EcoCyc is a bioinformatics database available at [EcoCyc.org](http://EcoCyc.org) that describes the genome and the biochemical machinery of *E. coli* K-12 MG 1655.

Best EcoCyc accession protein IDs were used for omics data analysis in EcoCyc. Paint multiomics data onto a Pathway Collage options were used to generate a user-customizable diagram containing a set of pathways of interest, overlaid with multiomics data.

Transmission Electron Microscopy Observations {#S2.SS9}
---------------------------------------------

Cells were fixed in cold 0.05 M Hepes buffer, pH 7.4, containing 2% glutaraldehyde and 2% formaldehyde added in Transwell systems. To prevent biofilm disorganization during following TEM embedding procedure, the membranes with biofilm were carefully cut with a razor blade, and these pieces were laid in a drop of 3% sodium alginate (in 0.05 M Hepes buffer, pH 7.4) and immediately solidified with CaCl~2~ 0.2 M. The samples were than repeatedly rinsed in the same Hepes buffer, postfixed in 1% osmium tetroxide, for 1 h at 4°C, dehydrated in ethanol, and embedded in London White resin. Ultrathin sections, obtained using a Reichert Jung Ultracut E microtome, were stained with 3% uranyl-acetate and lead citrate. Observations were performed with an EFTEM LEO 912AB transmission electron microscope (Zeiss, Jena, Germany) operating at 80 kV.

Results and Discussion {#S3}
======================

*E. coli* Biofilm Proteome Under AgNPs Treatments {#S3.SS1}
-------------------------------------------------

To gain insights into the response of *E. coli* to AgNPs, we compared the total biofilm proteome of four different samples: untreated biofilm (control), biofilm treated with AgNPs for 24 h (acute treatment), biofilm grown in the presence of AgNPs for 96 h (chronic treatment), and biofilm grown in the presence of AgNPs for 72 h and retreated with a higher dose of AgNPs for 24 h (chronic + acute treatment). Among the 1,917 proteins identified, 212 (11.26%) were significantly differentially expressed proteins (ANOVA test, FDR of 5%) ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

Principal Component Analysis and Hierarchical Clustering {#S3.SS2}
--------------------------------------------------------

Principal component analysis of the identified proteins across all samples revealed that the proteome of biofilms under different AgNP exposure assembled separately from each other into distinctly isolated clusters ([Figure 1](#F1){ref-type="fig"}). The Venn diagram in [Figure 2](#F2){ref-type="fig"} compared the number of expressed proteins across all treatments, showing common and unique proteins among the different exposure conditions. In particular, the Venn diagram showed 1,856 proteins (96.9%) commonly regulated in all the treatments.

![Principal component analysis (PCA) score plot of total proteome data. Samples with different treatments (control, acute, chronic, chronic + acute) were indicated by colors. *X*-axis and *Y*-axis were labeled with the first principal component and the second principal component, accounting for 33.4 and 29.1% total variation, respectively.](fmicb-10-02709-g001){#F1}

![Venn diagrams of the identified and quantified proteins in the four treatments.](fmicb-10-02709-g002){#F2}

We also performed a hierarchical clustering analysis and produced a heatmap to identify groups of proteins that display similar expression patterns across all treatments. The hierarchical clustering of the 212 significantly differentially expressed proteins revealed distinct expression patterns ([Figure 3](#F3){ref-type="fig"}). Heat map showed the clustered data, where each colored cell represents the protein abundance value. Column-wise clustering of triplicate measurements for each treatment demonstrated that biological variation was greater in the most severe experimental AgNP treatment considered (chronic + acute treatment) with respect to the control. Row-wise clustering revealed different protein groups based on the modulation of their expression. Eight expression clusters of interest with their relative intensity values are shown in [Figure 4](#F4){ref-type="fig"}.

![Heatmap and hierarchical clustering of 212 differentially expressed proteins (DEPs) with false discovery rate (FDR) of 5%. Colors ranging from green to red represent protein abundance from the highest level of downregulation to the highest level of upregulation, respectively.](fmicb-10-02709-g003){#F3}

![Eight most interesting and prominent expression profiles found in cluster analysis. Differentially expressed proteins (DEPs) belonging to each profile are represented by colored lines.](fmicb-10-02709-g004){#F4}

Clusters 1a and 1b were composed of proteins with increasing and decreasing abundances after all AgNP treatments, respectively. Clusters 2a and 2b included proteins that decrease and increase only under the chronic + acute AgNP treatment, respectively. Clusters 3a and 3b showed proteins after chronic treatments with decreasing and increasing abundances, respectively. Clusters 4a and 4b represented proteins with low or high abundance after acute AgNP treatment, respectively.

[Table 1](#T1){ref-type="table"} summarizes the observed main effects and the corresponding proteins. [Supplementary Table S2](#TS2){ref-type="supplementary-material"} lists all proteins belonging to the eight expression clusters and their respective localizations, intensity values, and log2 fold changes (log2FC). Minimum log2FC considered in this study were −2.56 and 2.21, which are very high values ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}).

###### 

Main effects observed and, for each type of treatment, the proteins related.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cluster n.**    **Type of treatments**                  **Biofilm alterations**                                              **Cell wall/membrane alterations**                       **Response to stress**                                   **DNA damage**                           **Glucose utilization**
  ----------------- --------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ---------------------------------------- -------------------------------------------
  Clusters 1a--1b   All AgNPs treatments                    ↓ 2-methylcitrate synthase (N3MZ53; log2FC = −2.98, −3.06, −3.21)\   ↓ ABC transporter-binding protein MlaB\                  (↓ GTP cyclohydrolase II\                                --                                       ↓ Malate dehydrogenase\
                                                            ↓ GTP cyclohydrolase II (W8SSB7; log2FC = −3.32, −3.21, −3.21)\      (N2GWD3; log2FC = -5.95, −5.68, −5.84)\                  (W8SSB7; log2FC = −3.21, 3.21, 3.21)\                                                             (Q5MDC1; log2FC = −6,93, 7.14, 6.87)\
                                                            ↑Glyoxalase I (T9A3H1; log2FC = 4.57, 4.44, 4.43)                    ↑ 1-Acylglycerol-3-phosphate *O*-acyltransferase\        ↓ TusD subunit of the sulfur transfer protein complex\                                            (Sugar phosphatase\
                                                                                                                                 (X7PK56; log2FC = 4.74, 4.80, 4.82)                      (W8TUH8; log2FC = −3.68, 2.90, 3.60)                                                              (X7PPK7; log2FC = −3.82, −3.75, −3.93)

  Clusters 2a--2b   Only chronic + acute AgNPs treatments   ↓ Fimbrial proteins\                                                 ↓ [L]{.smallcaps},[D]{.smallcaps}-transpeptidase LdtD\   ↓ Potassium efflux system KefA\                          --                                       ↑ Sugar transport-related regulator SgrR\
                                                            (D7ZQU6; log2FC = 0.07, −0.38, −4.24)\                               (A0A125X4Z9; log2FC = −0.20, −0.03, −4.18)\              (V1AK89; log2FC = 0.11, 0.01, −4.01)\                                                             (V1AK56; log2FC = 0.51, −0.29, 2.46)
                                                            ↓ Beta-glucuronidase\                                                ↓ Bacteriophage N4 receptor\                             (↓ PutA protein\                                                                                  
                                                            (F4TGG1; log2FC = −0.01, −0.02, −3.98)\                              (L3QSY0; log2FCtransporter\                              (V6FL94; log2FC = 0.34, 0.50, −4.28)\                                                             
                                                            ↑ UTP-glucose-1-phosphate uridylyltransferase\                       (W8TQQ2; log2FC = −0.21, −0.14, −5.26)\                  ↑ Multiple antibiotic resistance regulators MarR\                                                 
                                                            (W1FRC5; log2FC = −0.14, 0.24, 7.26)\                                (Phosphate acyltransferase\                              (V1AQH4; log2FC = 0.33, 0.42, 4.65)                                                               
                                                            ↑ Disulfide bond reductase\                                          (W1HGW9; log2FC = −0.44, −0.43, −5.28)                                                                                                                     
                                                            (H4HYU4; log2FC = −0.51, 0.27, 7.64)                                                                                                                                                                                            

  Clusters 3a--3b   Only chronic treatments                 ↓ C-di-GMP phosphodiesterase YhjK\                                   --                                                       --                                                       ↑ Formamidopyrimidine-DNA glycosylase\   --
                                                            (H9UY84; log2FC = −0.26, −3.83, −3.41)\                                                                                                                                                (X7NZ47; FC = 0.33, 7.80, 6.45)          
                                                            (↑ Cell division activator (CedA)\                                                                                                                                                                                              
                                                            (W8TE37; log2FC = 0.24, −3.05, −3.25)\                                                                                                                                                                                          
                                                            ↑ Biofilm regulator protein bssR\                                                                                                                                                                                               
                                                            (W1EUF9; log2FC = 0.33, 7.80, 6.45)                                                                                                                                                                                             

  Clusters 4a--4b   Only acute treatments                   ↓ Flagellar brake protein YcgR\                                      ↓ Tetratricopeptide repeat (TPR) region\                 --                                                       ↓ Primosomal protein\                    --
                                                            (V0AGY1; log2FC = −2.51, 0.47, −2.90)\                               (V1ALG4; log2FC = −5.79, −0.25, −5.01)                                                                            (X7PUN5; log2FC = −4.00, −0.78, −3.66)   
                                                            ↓ Tetratricopeptide repeat (TPR) region\                                                                                                                                                                                        
                                                            (V1ALG4; log2FC = −5.79, −0.25, −5.01)\                                                                                                                                                                                         
                                                            ↑ Sensor kinase protein RcsC\                                                                                                                                                                                                   
                                                            (F4SG61; log2FC = 3.34, 0.21, 3.70)\                                                                                                                                                                                            
                                                            ↑ Elongation factor Tu\                                                                                                                                                                                                         
                                                            (A0A0F3TYE0; FC = 1.15, 0.98, 1.21)\                                                                                                                                                                                            
                                                            ↑ Permease-cytosine transporter\                                                                                                                                                                                                
                                                            (A0A070SLJ2; log2FC = 3.36, −0.47, 4.90)\                                                                                                                                                                                       
                                                            ↑ Dipeptide transport system permease protein dppB\                                                                                                                                                                             
                                                            (W1XD85; log2FC = 3.10, −0.93, 2.98)                                                                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For each protein entry name (

www.uniprot.org

) and log2 fold changes (log2FC) (respectively: chronic treatment vs. control, acute treatment vs. control, chronic + acute treatment vs. control) are reported.

### Clusters 1a and 1b {#S3.SS2.SSS1}

Clusters 1a and 1b consisted of 16 and 14 proteins, respectively, the abundances of which decreased and increased under AgNP exposure, regardless of the nature of treatment.

In cluster 1a, we found downregulation of proteins related to biofilm formation that confirmed the biofilm alterations caused by AgNPs reported by [@B17]. In particular, the protein MlaB, a part of the ABC transporter complex MlaFEDB, is a small cytoplasmic protein that is very important for both the proper assembly and activity of the ABC complex ([@B55]). When ABC complex is altered, the plasma membrane shows defects in phospholipid asymmetry and slow rates of trafficking of other membrane components, especially the phosphatidylcholine ([@B20]). Phosphatidylcholine has been found in many bacteria for its influence on motility and biofilm formation ([@B22]). In all AgNP treatments, we also observed the downregulation of 2-methylcitrate synthase and protein guanosine-5′-triphosphate (GTP) cyclohydrolase II, both of which have been shown to be involved in biofilm formation ([@B44]; [@B30]).

The GTP cyclohydrolase II in *E. coli* is regulated by SoxRS system, the major pathway for superoxide stress response ([@B23]). This finding suggested that exposure to AgNPs increased oxidative stress in biofilms. In fact, it has been demonstrated that *ribA*, the gene encoding GTP cyclohydrolase II, is involved in the removal of 8-oxo-dGTP, which is a toxic product generated by ROS-mediated oxidation of the guanine nucleotide pool ([@B69]). GTP cyclohydrolase II protein also catalyzes the initial steps of the riboflavin biosynthesis pathway. Riboflavin (vitamin B~2~) is the direct precursor of the flavin cofactors flavin mononucleotide and flavin adenine dinucleotide. Flavin mononucleotide and flavin adenine dinucleotide accept electrons during oxidation of various compounds, such as amino acids, carbohydrates, and fatty acids. These cofactors are also required in redox reactions during DNA repair ([@B65]).

TusD subunit of the sulfur transfer protein complex belonged to cluster 1a. Introducing thiomodifications to transfer ribonucleic acid (tRNA), the TusD subunit ensures a higher stability of tRNA, enhances the translation efficiency, and prevents the frameshifting during translation ([@B10]). In addition, the end turnover of tRNA in *E. coli* is reported as one of the first responses to stress ([@B31]; [@B59]).

In the biofilm microbiota, the gene expression is characterized by high abundance of transcripts, where most of them are related to glucose utilization, peptide degradation, and amino acid transport ([@B45]). We found a reduction in the abundance of key enzymes of glucose and glucose-1-phosphate degradation pathways, such as the malate dehydrogenase and the sugar phosphatase ([@B62]). These findings suggested an alteration of the metabolic activity. In the tricarboxylic acid cycle, malate dehydrogenase catalyzes the reversible oxidation of malate to generate oxaloacetate using nicotine adenine dinucleotide (NAD+) as an electron acceptor ([@B51]). Decreased gluconeogenic activity might indicate a decreased requirement for new amino sugars for cell wall synthesis. This observation corresponded with the decreased expression of genes involved in cell wall synthesis and cell division as found by [@B8].

Cluster 1b grouped all upregulated proteins in all AgNP treatments. In this cluster, we observed an upregulation of the glyoxalase I. Studies by [@B42] and [@B50] reported that this enzyme is upregulated in biofilms, and it can also act in the detoxification of methylglyoxal (MG), which is a side product of several metabolic pathways. The toxicity of MG is believed to be attributed to its ability to interact with the nucleophilic centers of macromolecules, such as deoxyribonucleic acid (DNA) ([@B12]). In bacteria like *E. coli*, the glutathione-dependent glyoxalase I--II pathway is the primary route for MG detoxification. During this detoxification process, the glutathione is restored because it is an important cellular antioxidant often used for biofilm protection ([@B42]).

The observed upregulation of the protein 1-acylglycerol-3-phosphate *O*-acyltransferase indicated an activation of the phospholipid biosynthesis pathway through the cytidine diphosphate-diacylglycerol intermediate. In this pathway, the 1,2-diacyl-*sn*-glycerol-3-phosphate is converted to its activated form, the cytidine diphosphate-diacylglycerol, which is an important intermediate in the biosynthesis of all membrane glycerophospholipids ([@B54]).

### Clusters 2a and 2b {#S3.SS2.SSS2}

Clusters 2a and 2b illustrated 13 and 26 proteins after AgNP chronic + acute treatment that decreased and increased, respectively.

In cluster 2a, we found lower amounts of proteins related to cell membrane. This finding supports the evidence indicating that the cell membrane is one of the main targets of the AgNPs. Other membrane-related proteins such as the bacteriophage N4 receptor and the [L]{.smallcaps}-arginine ABC transporter-periplasmic binding protein were some of these downregulated proteins. Moreover, to confirm the toxic effect of AgNPs chronic + acute exposure on cell membrane, we observed the downregulation of a phosphate acyltransferase. This protein is involved in fatty acids/phospholipid biosynthesis that possibly contributes to reducing membrane fluidity and stability ([@B37]).

Bacterial cell wall also seemed to be altered. In AgNP-treated biofilm, we observed the downregulation of the [L]{.smallcaps},[D]{.smallcaps}-transpeptidase (LdtD), which is the key enzyme in the peptidoglycan maturation pathway ([@B60]).

The lower adherence of cells on the biofilm and the different distribution patterns within the biofilms observed after 96 h of AgNP exposure ([@B17]) were also confirmed by proteomic analyses. In fact, chronic and acute AgNP treatments caused the downregulation of some proteins that have a key role in bacterial adhesion, such as flagellins and fimbrial proteins. Flagellum-mediated motility contributes to *E. coli* virulence by enabling the bacterium to escape host immune responses and to colonize new sites within the urinary tract ([@B26]). *E. coli* fimbrial proteins mediate the binding to receptor structures allowing the bacteria to colonize various host tissues ([@B24]). The investigated *E. coli* flagellin mutant strains produced less biofilm than the wild-type strain ([@B71]).

Beta-glucuronidase was another protein that we found to be downregulated in AgNP-treated samples. β-Glucuronidase and phospholipase are factors in creating colonization surface that facilitate bacteremia and severe infections ([@B49]; [@B5]).

A transcriptional repressor of the proline utilization regulon (*put*), the PutA protein, belonged to cluster 2a. Proline metabolism strongly influences the oxidative stress tolerance in *E. coli.* As a consequence, *putA* mutant strains are significantly more sensitive to oxidative stress than the wild-type strains, and the overexpression of *putA* restores the oxidative stress resistance ([@B66]). Thus, the decrease in the protein PutA under chronic + acute treatments might expose the biofilm to oxidative stress. [@B17] observed increased ROS levels at 96 h in anaerobic biofilms subjected to both AgNP acute and chronic treatments at 82 and 55% higher than the control, respectively. However, ROS increase under the acute treatment was more evident than the chronic one. [@B7] reported that, under anaerobic conditions, there is a lower production of ROS, which did not affect *Pseudomonas aeruginosa* viability. However, the lack of deleterious mechanisms induced by ROS could cause the adaptation of bacteria and changes in the microbiomes ([@B33]). The relationships between oxidative stress and biofilm development have been widely discussed by [@B15].

The potassium efflux system KefA domain protein, which is downregulated in this cluster, has a pivotal role in the survivability of bacteria after toxic electrophile exposure. This protein is part of the bacterial protection system, where the electrophiles are detoxified by modulation of the cellular pH ([@B11]; [@B36]). [@B67] evaluated the active detachment mechanism in the dispersal of *P. aeruginosa* biofilms caused by glutathione-gated potassium efflux, showing biofilm detachment by the activation of glutathione-gated potassium efflux.

Cluster 2b showed the change in abundance of sugar-transport-related regulator, which indicated the alteration of glucose metabolism as also reported in cluster 1. This regulator coordinates the response to glucose-phosphate stress, a condition that occurs when glucose-6-phosphate is accumulated intracellularly and unbroken through the glycolytic pathway ([@B58]).

Among upregulated proteins belonging to cluster 2b, we found the disulfide bond reductase, the triosephosphate isomerase, and the uridine-5′-triphosphate-glucose-1-phosphate uridylyltransferase (*UTP*-glucose-1-phosphate uridylyltrans ferase). The latter protein catalyzes the formation of uridine diphosphate-glucose (UDP-glucose) from glucose-1-phosphate and UTP, and it is also required for biofilm formation ([@B27]). In biofilm and planktonic cultures of *Staphylococcus aureus*, the triosephosphate isomerases were differentially expressed as confirmed by Northern blot analysis ([@B3]). The altered disulfide bond reductase seems to be involved in the reduction in disulfide bonds between proteins and small molecules ([@B29]). The disulfide bond formation is also required for biofilm formation and pilus assembly as observed in *Actinomyces oris* biofilms ([@B28]).

### Clusters 3a and 3b {#S3.SS2.SSS3}

The clusters 3a and 3b showed eight proteins that were up- and downregulated by the chronic treatments, respectively.

[@B17] showed that biofilm grown in the presence of AgNPs for 96 h resulted in a 42.8 ± 11.1% decrease in thickness. Proteomic analysis confirmed this result, and in fact, we observed that, after 96 h of AgNP exposure, different proteins involved in biofilm growth were downregulated (cluster 3a). One of these proteins was the cyclic di-guanylate monophosphate (c-di-GMP) phosphodiesterase (YhjK), which is one of the proteins involved in bacteria motility and biofilm formation ([@B32]). Bacteria modulates the intracellular levels of the second messenger c-di-GMP levels to regulate the transition between motile and sessile states. In response to extracellular signals, YhjK is able to modulate the levels of c-di-GMP, mediating the conversion from motile to sessile states ([@B48]).

In cluster 3a, we also found the involvement of the cell division activator in the reactivation of the DnaA protein, which is one of the main factors controlling the initiation of chromosomal DNA replication ([@B1]).

The regulator of biofilm through signal secretion protein (BssR), belonging to the upregulated proteins (cluster 3b), is also involved in biofilm formation in *E. coli*. This protein reduces bacterial biofilm by indole regulation ([@B52]).

The formamidopyrimidine-DNA glycosylase also belonged to cluster 3b. This molecule is a DNA repair enzyme that efficiently repairs purines- and pyrimidine-derived lesions induced by hydroxyl radical in DNA ([@B43]), suggesting DNA damages due to AgNP chronic exposure.

### Clusters 4a and 4b {#S3.SS2.SSS4}

The clusters 4a and 4b showed eight and six proteins that were up- and downregulated by the acute AgNP treatments, respectively.

The primosomal protein, one of the several cell surface proteins required for a stable DNA replication ([@B70]), is downregulated only by the acute treatment (cluster 4a).

Another protein downregulated in our analysis was the flagellar brake protein YcgR. This protein is involved in biofilm formation, in particular motility inhibition ([@B47]; [@B41]).

We also found lower amount of the PgaA, which is a tetratricopeptide-repeat-containing outer membrane protein. PgaA forms secretion pores in the outer membrane and translocates the dPNAG polymer from the periplasm to the cell surface. Tetratricopeptide repeat domain of PgaA binds directly to the *N*-deacetylase PgaB and affects critically biofilm formation ([@B61]; [@B21]).

Among the upregulated proteins in cluster 4b, we found the permease and dipeptide transport system permease protein DppB, also known as dipeptide ABC transporter. [@B72] showed that the inactivation of *lm.G_1771* gene, which encodes for a putative ABC transporter permease, increased *Listeria monocytogenes* biofilm.

Sensor kinase protein (RcsC) was also upregulated. It plays an important role in biofilm formation by remodeling the bacterial surface during growth on a solid surface ([@B13]).

We also observed an increase in the amount of the elongation factor Tu, a prokaryotic elongation factor responsible for catalyzing the binding of an aminoacyl-tRNA to the ribosome ([@B19]; [@B2]). [@B53] showed that the elongation factor Tu is highly expressed in *Streptococcus mutans* biofilms.

TEM Analysis of *E. coli* Biofilm Under AgNP Treatments {#S3.SS3}
-------------------------------------------------------

In control samples, TEM analyses showed that the bacterial cells forming the biofilm have different morphologies. Cells near the polycarbonate membrane (inner biofilm, [Figure 5A](#F5){ref-type="fig"}) showed uniform granular cytoplasm ([@B40]). Cell walls had a typical *E. coli* wall structure, where the periplasmic space (PS) is sandwiched between the plasma membrane and the outer membrane (OM), while the peptidoglycan layer is localized under the OM ([Figure 5C](#F5){ref-type="fig"}) ([@B4]; [@B46]). Farther away from the polycarbonate membrane (outer biofilm, [Figures 5B,D](#F5){ref-type="fig"}), biofilm cells revealed a more heterogeneous cytoplasm with a granular region surrounding the nucleoid clear area ([Figures 5B,D,F](#F5){ref-type="fig"}), as in the growing cells observed by [@B40]. After AgNP treatment, cytoplasm morphology did not change both in the inner and the outer biofilm layers. However, in the outer biofilm, cell wall OM appeared to be more electron dense than the control ([Figure 5F](#F5){ref-type="fig"}, arrow), suggesting AgNP deposition. Cell wall of the inner biofilm, on the contrary, was similar to the control (compare [Figures 5C,E](#F5){ref-type="fig"}). The presence of an electron-dense OM was also evident in samples exposed to chronic and chronic + acute treatments ([Figure 6](#F6){ref-type="fig"}). The cell wall thickness under all treatments is reported in [Figure 7](#F7){ref-type="fig"}.

![Transmission electron microscopy (TEM) analysis of untreated biofilm (control) and biofilm treated with AgNPs for 24 h (acute treatment). **(A)** Low magnification of inner biofilm showing a uniform granular cytoplasm. **(B)** Low magnification of outer biofilm showing granular cytoplasm surrounding nucleoid. **(C,D)** Inner and outer biofilm showing a typical Gram-negative cell walls, respectively. ps, periplasmic space; black arrow: outer membrane; white arrow: peptidoglycan layers. **(E,F)** Biofilm after AgNP acute treatment. Inner biofilm appeared similar to control **(E)**, while outer biofilm showed a more electrondense outer membrane (arrow). The peptidoglycan layers were less evident. Magnification bars: **(A,B)** 1 μm; **(C--F)** 500 nm.](fmicb-10-02709-g005){#F5}

![Transmission electron microscopy (TEM) analysis of biofilm grown in the presence of AgNPs for 96 h (chronic treatment) and biofilm grown in the presence of AgNPs for 96 h and treated again for 24 h with AgNPs (chronic + acute treatment). **(A,B)** Inner and outer biofilm showing a modified cell wall with a more electrondense outer membrane (black arrows) and a disorganized peptidoglycan layers (white arrows), respectively. **(C,D)** Biofilm chronic + acute AgNP treatment. No differences are observed compared to biofilm grown in the presence of AgNPs for 96 h (chronic treatment) (outer membrane: black arrows). Magnification bars: **(A--F)** 500 nm.](fmicb-10-02709-g006){#F6}

![Wall thickness of inner and outer biofilm cells under different treatments. Data represent the mean of independent measurements. Different superscript letters indicate statistically significant differences between conditions.](fmicb-10-02709-g007){#F7}

Conclusion {#S4}
==========

In this study, we demonstrated that AgNPs led to changes in protein expression that is directly related to biofilm formation and maturation. In particular, we observed the downregulation of proteins that have key roles in bacterial adhesion, such as flagellins and fimbrial proteins, which are necessary for biofilm formation ([@B71]).

The proteomic investigation revealed many altered membrane- and cell-wall-associated proteins. This result was further confirmed by the reduction in the cell wall thickness, as observed in TEM analyses. The presence of AgNP aggregates in the cytoplasm was not detected in TEM analyses.

Glucose utilization pathways were also altered, and some evidence indicated the possibility of DNA damages, as shown by the upregulation of proteins related to the DNA repair system.

Furthermore, to deepen the understanding of AgNP effects on the gut interactive ecosystem, the proteomic response of Caco-2 intestinal cells to AgNP sublethal concentrations will be carried out.
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